[go: up one dir, main page]

IN2012DN01292A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01292A
IN2012DN01292A IN1292DEN2012A IN2012DN01292A IN 2012DN01292 A IN2012DN01292 A IN 2012DN01292A IN 1292DEN2012 A IN1292DEN2012 A IN 1292DEN2012A IN 2012DN01292 A IN2012DN01292 A IN 2012DN01292A
Authority
IN
India
Prior art keywords
therapy
preparing
processes
compound
formula
Prior art date
Application number
Inventor
Simon Craig Andrew
Zarah Ismail Salima
Maxwell Lawrence Ronnie
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of IN2012DN01292A publication Critical patent/IN2012DN01292A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The invention relates to the compound of formula (I) in a crystalline anhydrate form, pharmaceutical formulations containing them, their use in therapy and processes for preparing the same.
IN1292DEN2012 2009-08-27 2010-08-25 IN2012DN01292A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23743509P 2009-08-27 2009-08-27
PCT/EP2010/062420 WO2011023733A1 (en) 2009-08-27 2010-08-25 Anhydrate forms of a pyridine derivative

Publications (1)

Publication Number Publication Date
IN2012DN01292A true IN2012DN01292A (en) 2015-06-05

Family

ID=42790943

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1292DEN2012 IN2012DN01292A (en) 2009-08-27 2010-08-25

Country Status (18)

Country Link
US (1) US8796269B2 (en)
EP (1) EP2470545B1 (en)
JP (3) JP2013503134A (en)
KR (1) KR20120056258A (en)
CN (1) CN102639536B (en)
AU (1) AU2010288502B2 (en)
BR (1) BR112012003435A2 (en)
CA (1) CA2772168C (en)
DK (1) DK2470545T3 (en)
EA (1) EA021411B1 (en)
ES (1) ES2440938T3 (en)
IL (1) IL217922A (en)
IN (1) IN2012DN01292A (en)
MX (1) MX2012002369A (en)
PL (1) PL2470545T3 (en)
SG (1) SG178231A1 (en)
WO (1) WO2011023733A1 (en)
ZA (1) ZA201200812B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011023733A1 (en) * 2009-08-27 2011-03-03 Glaxosmithkline Llc Anhydrate forms of a pyridine derivative
ES2879375T3 (en) * 2014-06-25 2021-11-22 Univ Emory Conditioned fear management procedures with neurokinin receptor antagonists
CA2984591A1 (en) * 2015-05-18 2016-11-24 Nerre Therapeutics Limited Dual nk-1/nk-3 receptor antagonists for the treatment of sex-hormone-dependent diseases
BR112019012300A2 (en) * 2016-12-15 2019-11-12 Glaxosmithkline Intellectual Property Development Limited nrf2 activators
SG11202008226YA (en) 2018-03-14 2020-09-29 Kandy Therapeutics Ltd Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists
WO2021030335A1 (en) * 2019-08-12 2021-02-18 Millendo Therapeutics, Inc. A stereoisomerically pure nk-3 receptor antagonist and crystalline forms thereof
JOP20220111A1 (en) 2019-11-15 2023-01-30 Kandy Therapeutics Ltd New chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key in-termediate of NT-814
EP4431512A1 (en) 2023-03-16 2024-09-18 Bayer Consumer Care AG Novel dual nk-1/nk-3 receptor antagonists
WO2025242585A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant
WO2025242584A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag A stable soft gelatin capsule formulation for elinzanetant
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60014216T2 (en) * 1999-02-24 2006-03-02 F. Hoffmann-La Roche Ag 4-phenylpyridine derivatives and their use as NK-1 receptor antagonists
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
CN100562320C (en) * 2003-01-31 2009-11-25 弗·哈夫曼-拉罗切有限公司 2-(3,5-di-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1λ6-thiomorpholin-4-yl)-4-(4-fluoro -New crystal modification of -2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
EP1643998B1 (en) * 2003-07-03 2007-08-29 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists for treating schizophrenia
JO2722B1 (en) * 2005-09-09 2013-09-15 سميث كلاين بيتشام كوربوريشن Novel compounds
AU2008346110A1 (en) * 2007-12-11 2009-07-16 Cipla Ltd. Crystalline polymorphic forms of zopiclone, processes for their preparation and their pharmaceutical compositions
GB0814340D0 (en) 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
WO2011023733A1 (en) * 2009-08-27 2011-03-03 Glaxosmithkline Llc Anhydrate forms of a pyridine derivative
JP6342662B2 (en) * 2014-01-29 2018-06-13 京セラ株式会社 Drill and method of manufacturing cut product using the same

Also Published As

Publication number Publication date
AU2010288502A1 (en) 2012-02-23
MX2012002369A (en) 2012-03-29
CN102639536B (en) 2015-03-18
CN102639536A (en) 2012-08-15
IL217922A0 (en) 2012-03-29
CA2772168C (en) 2019-01-08
JP6404186B2 (en) 2018-10-10
KR20120056258A (en) 2012-06-01
EA021411B1 (en) 2015-06-30
DK2470545T3 (en) 2014-01-13
IL217922A (en) 2016-06-30
EP2470545B1 (en) 2013-10-09
BR112012003435A2 (en) 2016-02-23
CA2772168A1 (en) 2011-03-03
ZA201200812B (en) 2013-03-27
WO2011023733A1 (en) 2011-03-03
EA201270302A1 (en) 2012-07-30
ES2440938T3 (en) 2014-01-31
US20120157450A1 (en) 2012-06-21
JP2017193564A (en) 2017-10-26
JP2016000739A (en) 2016-01-07
EP2470545A1 (en) 2012-07-04
AU2010288502B2 (en) 2013-12-12
PL2470545T3 (en) 2014-03-31
SG178231A1 (en) 2012-03-29
JP2013503134A (en) 2013-01-31
US8796269B2 (en) 2014-08-05

Similar Documents

Publication Publication Date Title
IN2012DN01292A (en)
MX2011011661A (en) Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750.
MX2011008864A (en) Sulfonylated tetrahydroazolopyrazines and their use as medicinal products.
NZ608116A (en) Triazine-oxadiazoles
MY149731A (en) Compounds
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
MX2012013274A (en) Novel pyrimidine derivatives.
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
IN2012DN03182A (en)
MX2010002461A (en) (carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament.
MX2010002419A (en) (cyclopropyl-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament.
IN2014CN04530A (en)
MY187718A (en) Pharmaceutical formulations
IN2012DN02139A (en)
MX2013010898A (en) Novel pyrimidine derivatives.
MX2010002210A (en) Catecholamine derivatives and prodrugs thereof.
IN2015DN01119A (en)
MX2011011776A (en) Triptolide prodrugs.
MY160625A (en) Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation
JO2682B1 (en) 7-ALkynyl-1,8-Naphthyridone Derivatives, Preparation Thereof And Therapeutic Use Thereof
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
MX2013006670A (en) 2-carboxamide-4-piperazinyl-benzofuran derivative.
MX2012007253A (en) Tricyclic derivatives and their pharmaceutical use and compositions.
MX2011008126A (en) Substituted indole compounds as bradykinin receptor 1 modulators.
IN2012DN02698A (en)